These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 19826111)
21. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Tefferi A; Barbui T Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718 [TBL] [Abstract][Full Text] [Related]
22. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685 [TBL] [Abstract][Full Text] [Related]
23. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. Zhang ZR; Duan YC Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389 [TBL] [Abstract][Full Text] [Related]
24. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298 [TBL] [Abstract][Full Text] [Related]
25. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b. Shimoda K; Qin A; Komatsu N; Kirito K Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434 [TBL] [Abstract][Full Text] [Related]
27. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA; Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581 [TBL] [Abstract][Full Text] [Related]
28. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066 [TBL] [Abstract][Full Text] [Related]
29. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568 [TBL] [Abstract][Full Text] [Related]
30. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451 [TBL] [Abstract][Full Text] [Related]